Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

In 2024, drug makers lowered the cost of dozens of common medications to avoid penalties imposed by the American Rescue Plan, Katie Thomas of ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...

Gov. Newsom in 2020 signed a law allowing California to manufacture its own insulin, an effort to bring down the cost of the ...

Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on patients' ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...